CD55-Interaction partners and the uses thereof
AssigneeCancer Reasearch Technology Limited
InventorGillian Durrant
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a binding member which binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to SCR1 and SCR2 of CD55 and neutralising CD55 and making cancer cells susceptible to complement mediated attack.
Claims17
1-9. (canceled)
A combined preparation comprising a naked binding member, which binds to both SCR1 and SCR2 of CD55, and an active agent, said combined preparation being for simultaneous, separate or sequential use in the treatment of cancer, wherein said active agent is a chemotherapeutic agent, a pain relief agent or an anti-emetic.
The combined preparation according to claim 13 wherein said active agent is an anti-CD20 antibody;
- an anti-VEGF antibody;
- an anti-CD171A antibody;
- an anti-CEA;
- anti-idiotypic mAb;
- an anti-HMFG anti-idiotypic mAb;
- an anti-EGFR antibody;
- or an anti-HER2 antibody.
(canceled)
A pharmaceutical composition for the treatment of cancer, wherein the composition comprises a naked binding member that binds to both SCR1 and SCR2 of CD55 and a pharmaceutically acceptable excipient, diluent or carrier.
(canceled)
A method of neutralizing the complement activation inhibition activity of CD55, comprising administration of a naked binding member which specifically binds to SCR1 and SCR2 of CD55.
A method of enhancing complement deposition comprising administration of a naked binding member which specifically binds to SCR1 and SCR2 of CD55.
A method of treating cancer comprising administration of a therapeutically effective amount of a naked binding member which specifically binds to SCR1 and SCR2 of CD55 to a mammal in need thereof.
(canceled)
Dependencies are inferred from the claim text.